Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.
Identifieur interne : 004578 ( PubMed/Checkpoint ); précédent : 004577; suivant : 004579Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.
Auteurs : D. Dressler [Allemagne] ; R O Oeljeschl Ger ; E. RütherSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Antipsychotic Agents (adverse effects), Baclofen (administration & dosage), Baclofen (therapeutic use), Blood-Brain Barrier, Drug Resistance, Dystonia (chemically induced), Dystonia (drug therapy), Female, GABA Agonists (administration & dosage), GABA Agonists (therapeutic use), Humans, Infusion Pumps, Implantable, Injections, Spinal, Middle Aged.
- MESH :
- chemical , administration & dosage : Baclofen, GABA Agonists.
- chemical , adverse effects : Antipsychotic Agents.
- chemical , therapeutic use : Baclofen, GABA Agonists.
- chemically induced : Dystonia.
- drug therapy : Dystonia.
- Blood-Brain Barrier, Drug Resistance, Female, Humans, Infusion Pumps, Implantable, Injections, Spinal, Middle Aged.
Abstract
Treatment of tardive dystonia with oral baclofen produces ambivalent and overall disappointing results. However, because only a small proportion of the baclofen penetrates into the central nervous system when administered orally, we tested whether it is possible to increase the efficacy of treatment by continuous intrathecal infusion of baclofen (CITB) in a patient with severe tardive axial dystonia unresponsive to conventional therapy. A dose of 100 micrograms/day improved muscle tone, head control, posture, and walking distance; electromyography showed a marked decrease of dystonic muscle activity with fully preserved voluntary muscle activity, and the patient reported substantial reduction of pain. Apart from some minor discomfort at the site of operation, no side effects were noted. Further studies should be encouraged to evaluate the usefulness of CITB for other patients with severe and otherwise untreatable tardive dystonia.
DOI: 10.1002/mds.870120416
PubMed: 9251078
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9251078Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.</title><author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D" last="Dressler">D. Dressler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Georg-August-University, Göttingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, Georg-August-University, Göttingen</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Göttingen</settlement></placeName></affiliation></author><author><name sortKey="Oeljeschl Ger, R O" sort="Oeljeschl Ger, R O" uniqKey="Oeljeschl Ger R" first="R O" last="Oeljeschl Ger">R O Oeljeschl Ger</name></author><author><name sortKey="Ruther, E" sort="Ruther, E" uniqKey="Ruther E" first="E" last="Rüther">E. Rüther</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9251078</idno><idno type="pmid">9251078</idno><idno type="doi">10.1002/mds.870120416</idno><idno type="wicri:Area/PubMed/Corpus">004634</idno><idno type="wicri:Area/PubMed/Curation">004634</idno><idno type="wicri:Area/PubMed/Checkpoint">004578</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.</title><author><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D" last="Dressler">D. Dressler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Psychiatry, Georg-August-University, Göttingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, Georg-August-University, Göttingen</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Göttingen</settlement></placeName></affiliation></author><author><name sortKey="Oeljeschl Ger, R O" sort="Oeljeschl Ger, R O" uniqKey="Oeljeschl Ger R" first="R O" last="Oeljeschl Ger">R O Oeljeschl Ger</name></author><author><name sortKey="Ruther, E" sort="Ruther, E" uniqKey="Ruther E" first="E" last="Rüther">E. Rüther</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic Agents (adverse effects)</term><term>Baclofen (administration & dosage)</term><term>Baclofen (therapeutic use)</term><term>Blood-Brain Barrier</term><term>Drug Resistance</term><term>Dystonia (chemically induced)</term><term>Dystonia (drug therapy)</term><term>Female</term><term>GABA Agonists (administration & dosage)</term><term>GABA Agonists (therapeutic use)</term><term>Humans</term><term>Infusion Pumps, Implantable</term><term>Injections, Spinal</term><term>Middle Aged</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Baclofen</term><term>GABA Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Baclofen</term><term>GABA Agonists</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Blood-Brain Barrier</term><term>Drug Resistance</term><term>Female</term><term>Humans</term><term>Infusion Pumps, Implantable</term><term>Injections, Spinal</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of tardive dystonia with oral baclofen produces ambivalent and overall disappointing results. However, because only a small proportion of the baclofen penetrates into the central nervous system when administered orally, we tested whether it is possible to increase the efficacy of treatment by continuous intrathecal infusion of baclofen (CITB) in a patient with severe tardive axial dystonia unresponsive to conventional therapy. A dose of 100 micrograms/day improved muscle tone, head control, posture, and walking distance; electromyography showed a marked decrease of dystonic muscle activity with fully preserved voluntary muscle activity, and the patient reported substantial reduction of pain. Apart from some minor discomfort at the site of operation, no side effects were noted. Further studies should be encouraged to evaluate the usefulness of CITB for other patients with severe and otherwise untreatable tardive dystonia.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9251078</PMID><DateCreated><Year>1997</Year><Month>10</Month><Day>14</Day></DateCreated><DateCompleted><Year>1997</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1997</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.</ArticleTitle><Pagination><MedlinePgn>585-7</MedlinePgn></Pagination><Abstract><AbstractText>Treatment of tardive dystonia with oral baclofen produces ambivalent and overall disappointing results. However, because only a small proportion of the baclofen penetrates into the central nervous system when administered orally, we tested whether it is possible to increase the efficacy of treatment by continuous intrathecal infusion of baclofen (CITB) in a patient with severe tardive axial dystonia unresponsive to conventional therapy. A dose of 100 micrograms/day improved muscle tone, head control, posture, and walking distance; electromyography showed a marked decrease of dystonic muscle activity with fully preserved voluntary muscle activity, and the patient reported substantial reduction of pain. Apart from some minor discomfort at the site of operation, no side effects were noted. Further studies should be encouraged to evaluate the usefulness of CITB for other patients with severe and otherwise untreatable tardive dystonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dressler</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Georg-August-University, Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeljeschläger</LastName><ForeName>R O</ForeName><Initials>RO</Initials></Author><Author ValidYN="Y"><LastName>Rüther</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018755">GABA Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>H789N3FKE8</RegistryNumber><NameOfSubstance UI="D001418">Baclofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001418">Baclofen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004351">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018755">GABA Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015918">Infusion Pumps, Implantable</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9251078</ArticleId><ArticleId IdType="doi">10.1002/mds.870120416</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Basse-Saxe</li></region><settlement><li>Göttingen</li></settlement></list><tree><noCountry><name sortKey="Oeljeschl Ger, R O" sort="Oeljeschl Ger, R O" uniqKey="Oeljeschl Ger R" first="R O" last="Oeljeschl Ger">R O Oeljeschl Ger</name><name sortKey="Ruther, E" sort="Ruther, E" uniqKey="Ruther E" first="E" last="Rüther">E. Rüther</name></noCountry><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Dressler, D" sort="Dressler, D" uniqKey="Dressler D" first="D" last="Dressler">D. Dressler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004578 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004578 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9251078
|texte= Severe tardive dystonia: treatment with continuous intrathecal baclofen administration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9251078" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |